电疗法和阿卡西西亚:对病例报告的综合文献综述
Hiroo Mukai1, Sayaka Kageyama, Gentaro Miura
1From the Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
The journal of ECT
|July 18, 2024
概括
电疗法 (ECT) 可能改善严重或晚期无神症,特别是在情绪障碍患者中. 然而,作为ECT的副作用,可能会出现过渡性无声症.
科学领域:
- 神经科学是一个神经科学.
- 精神病学是一个精神病学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿卡西西亚是一种令人痛苦的额外皮拉米德副作用,通常与抗精神病药物使用有关.
- 电疗法 (ECT) 对于治疗白内障,特别是耐治疗形式的疗效需要进一步研究.
研究的目的:
- 系统地审查电疗法 (ECT) 对患有阿卡西西亚的患者的影响.
- 评估ECT作为严重,晚期或抗精神病诱导的阿卡西西亚的潜在治疗方法.
主要方法:
- 在MEDLINE和Embase的系统文献搜索中,寻找与ECT相关的阿卡西西亚病例报告.
- 包含了9篇文章,详细介绍了15例阿卡西西亚病例及其与ECT的关联.
主要成果:
- 七篇文章 (10个案例) 报告说,在ECT后,阿卡西西亚显著改善,特别是在用抗精神病药物治疗情绪障碍患者中.
- 两篇文章 (5例) 描述了在ECT后发生的过渡性阿卡西西亚,治疗结果不一致,但没有观察到持续的病例.
结论:
- 电疗法 (ECT) 可能是治疗耐药性,晚期或严重的白血病的可行选择,特别是当它与情绪障碍并发时.
- 临床医生应该意识到ECT后可能出现过渡性白内障症,尽管它通常会消失.
- 需要进一步进行高质量的研究,以澄清ECT在阿卡西西亚管理中的确切作用.
更多相关视频
09:07Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
Published on: August 15, 2017
12.0K
04:29Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
Published on: January 7, 2019
28.5K
相关概念视频
01:30Electroconvulsive Therapy
30
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
30
01:20Antiepileptic Drugs: Potassium Channel Activators
162
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
162
01:26Psychosis: Goals of Pharmacotherapy
114
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
114
01:23Antidepressant Drugs: MAOIs and Other Agents
209
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
209
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
352
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
352